Novel block glycopolymers prepared as delivery nanocarriers for controlled release of bortezomib

Investigating the complexation propensity of self-assembling dipeptides with the anticancer peptide-drug Bortezomib: a computational study

The investigation of potential self-assembled peptides as carriers for the delivery of anticancer drug Bortezomib is the topic of the present study. The self-assembly of Bortezomib in water is examined using all-atom molecular dynamics simulations and corresponding experimental results from FESEM experiments. In addition, a series of dipeptides with a similar chemical formula to Bortezomib with hydrogel-forming ability are being investigated for their propensity to bind to the drug molecule. Dipeptides are divided into two classes, the protected FF (Fmoc-FF and Z-FF) and the LF-based (Cyclo-LF and LF) ones. The thermodynamic stability of the complexes formed in an aqueous environment, as well as key morphological features of the nanoassemblies are investigated at the molecular level. Binding enthalpy between Bortezomib and dipeptides follows the increasing order: LF < Cyclo-LF < Fmoc-FF < Z-FF under both van der Waals and electrostatic contributions. Protected FF dipeptides have a higher affinity for the drug molecule, which will favor its entrapment, giving them an edge over the LF based dipeptides. By evaluating the various measures, regarding both the binding between the two components and the eventual ability of controlled drug release, we conclude that the protected FF class is a more suitable candidate for drug release of Bortezomib, whereas among its two members, Fmoc-FF appears to be more promising. The selection of the optimal candidates based on the present computational study will be a stepping stone for future detailed experimental studies involving the encapsulation and controlled release of Bortezomib both in vitro and in vivo.

Water-soluble PEG segmented mannose-based macromolecules: Synthesis and their biocompatibility

The macromolecular architectures, namely mannose-based methacrylate acetyl-mannopyranoside and PEG block copolymers (AB type copolymer [PEG-b-PMAM], poly(ethyleneglycol)-b-poly(methacryl-2,3,4,6-tetra-O-acetyl-D-mannopyranoside and ABA type copolymer [PMAM-b-PEG-b-PMAM], poly(methacryl-2,3,4,6-tetra-O-acetyl-D-mannopyranoside-b-poly(ethyleneglycol)-b-poly(methacryl-2,3,4,6-tetra-O-acetyl-D-mannopyranoside) were synthesized by atom transfer radical polymerization (ATRP) method that were deacetylated to generate the corresponding water-soluble and biocompatible glycopolymer macromolecules. The molecular weight of acetyl and deacetylate macromolecules was in the range of 7083-9499 and 4659-6026, as determined by GPC and proton NMR spectra. The 5 % decomposition temperatures for acetylated methacrylate macromolecules (218-299 °C) were higher than the corresponding water-soluble macromolecules (204-248 °C). The conjugation of poly(methacryl-2,3,4,6-tetra-O-acetyl-D-mannopyranoside (PMAM) segment with the PEG block decreased the glass transition (Tg) value, and the water-soluble macromolecules displayed Tg in the range of 92-95 °C. The biocompatibility of the synthesized water-soluble mannose-based macromolecules was determined using Human Bone Derived Cells (HBDC) culture with the TCP (Tissue culture plastic) template as control. Using three different concentrations of the synthesized glycopolymers, HBDC's were cultured for 1, 3, and 7 days. The effect of mannomethacrylate macromolecules on mitochondrial activity of HBDC's was estimated using colorimetry that showed the conversion of MTS [3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide] to formazan (MTS assay). ABA type diblock copolymer architecture exhibited increased absorbance values of 3 and 7 day cultures at 1-100 M concentrations, with the highest values observed at a concentration of 1 M for day 3 cultures. The design of these novel mannose-based macromolecules is important for improving cell proliferation, cell adhesion, and osteointegration efficiency.

Recent Advances in the Application of ATRP in the Synthesis of Drug Delivery Systems

Advances in atom transfer radical polymerization (ATRP) have enabled the precise design and preparation of nanostructured polymeric materials for a variety of biomedical applications. This paper briefly summarizes recent developments in the synthesis of bio-therapeutics for drug delivery based on linear and branched block copolymers and bioconjugates using ATRP, which have been tested in drug delivery systems (DDSs) over the past decade. An important trend is the rapid development of a number of smart DDSs that can release bioactive materials in response to certain external stimuli, either physical (e.g., light, ultrasound, or temperature) or chemical factors (e.g., changes in pH values and/or environmental redox potential). The use of ATRPs in the synthesis of polymeric bioconjugates containing drugs, proteins, and nucleic acids, as well as systems applied in combination therapies, has also received considerable attention.

Tailor-made Glycopolymers via Reversible Deactivation Radical Polymerization: Design, Properties and Applications

Investigating the underlying mechanism of biological interactions using glycopolymer is becoming increasingly important owing to their unique recognition properties. The multivalent interactions between lectin and glycopolymer are significantly influenced by...

Polymeric Nanoparticles and Their Novel Modifications for Targeted Delivery of Bortezomib

Bortezomib (BTZ) as a specific proteasome inhibitor is used to inhibit proliferation and migration of tumor cell in variety of cancers. Targeted delivery of this drug not only would minimize its unwanted side effects but also might improve its efficacy. This purpose could be gotten through different pathways but using efficient carriers may be the best one without using any additional ingredients/ materials. Some polymer based nanoparticles with specific functional groups have the ability to interact with boronic acid moiety in BTZ. This reaction might play an important role not only in cancer targeting therapy but also in loading and release properties of this drug. Novel modification such as making multifunctional or pH-sensitive nanocarriers, may also improve anticancer effect of BTZ. This review might have remarkable effect on researchers’ consideration about other possible interactions between BTZ and polymeric nanocarriers that might have great effect on its remedy pathway. It has the ability to brought bright ideas to their minds for novel amendments about other drugs and delivery systems.

Enhancing the Therapeutic Efficacy of Bortezomib in Cancer Therapy Using Polymeric Nanostructures

:

Bortezomib (VELCADE®) is a boronate peptide and first-in-class proteasome inhibitor serving an important role in degenerating several intracellular proteins. It is a reversible inhibitor of the 26S proteasome, with antitumor activity and antiproliferative properties. This agent principally exerts its antineoplastic effects by inhibiting key players in the nuclear factor κB (NFκB) pathway involved in cell proliferation, apoptosis, and angiogenesis. This medication is used in the management of multiple myeloma. However, more recently, it has been used as a therapeutic option for mantle cell lymphoma. While promising, bortezomib has limited clinical applications due to its adverse effects (e.g., hematotoxicity and peripheral neuropathy) and low effectiveness in solid tumors resulting from its poor penetration into such masses and suboptimal pharmacokinetic parameters. Other limitations to bortezomib include its low chemical stability and bioavailability, which can be overcome by using nanoparticles for its delivery. Nanoparticle delivery systems can facilitate the targeted delivery of chemotherapeutic agents in high doses to the target site, while sparing healthy tissues. Therefore, this drug delivery system has provided a solution to circumvent the limitations faced with the delivery of traditional cancer chemotherapeutic agents. Our aim in this review was to describe polymer-based nanocarriers that can be used for the delivery of bortezomib in cancer chemotherapy.